Evidence map›Paper›PMID 40716957›Full record

Observational studyClinical & experimental ophthalmology2025

Outcomes After Switching to Faricimab in Neovascular Age-Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry.

Adrian Hunt, Yohei Hashimoto, Stephanie Young, Jennifer Arnold, Justin Game, Claire Hooper, Andrew Field, Richard Barry, Daniel Barthelmes, Mark Gillies

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical & experimental ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Adrian HuntThe Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-6261-4679
Yohei HashimotoThe Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Stephanie YoungGladesville Eye Specialists, Gladesville, New South Wales, Australia.
Jennifer ArnoldMarsden Eye Specialists, Parramatta, New South Wales, Australia.
Justin GamePort Macquarie Eye Centre, Port Macquarie, New South Wales, Australia.
Claire HooperThe Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Andrew FieldCairns Eye Surgery, Edge Hill, Queensland, Australia.
Richard BarryBlink Eye Clinic, Barton, Australian Capital Territory, Australia.
Daniel BarthelmesDepartment of Ophthalmology, University Hospital and University of Zurich, Zurich, Switzerland.
Mark GilliesThe Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

Funding

National Health and Medical Research Council NHMRC 2010-1012Royal Australian and New Zealand College of Ophthalmologists 2007-2009
6 · The paper itself

Abstract

backgroundWe aimed to describe 1-year outcomes of eyes switched to faricimab from first-generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD) in routine care.

methodsMulticentre, observational study of 383 eyes tracked in the Fight Retinal Blindness! registry switched to faricimab from aflibercept 2 mg, ranibizumab, or bevacizumab between 1st January-1st August 2023 in Australia.

resultsOne-year completion rates were high (335/383 [88%]). The proportion of choroidal neovascular (CNV) lesions graded as inactive increased from 39% at switch to 63% at 12 months (p < 0.01). Mean visual acuity (95% Confidence Interval) decreased from 70.0 (68.6, 71.5) to 68.4 (66.7, 70.1) logarithm of the minimum angle of resolution letters (both approx. 6/12). Mean treatment intervals increased from 7.2 to 10.5 weeks (p < 0.01). Eyes with active CNV at switch maintained mean VA -0.5 (-1.7, +0.7) letters; 50% were inactivated at 12 months. Eyes with inactive CNV at switch lost -3.5 (-5.0, -1.9) letters; 15% had reactivation at 12 months. Switchback occurred in 64/383 eyes (17%), predominantly to aflibercept 2 mg, that lost -1.9 letters without interval change at 12 months. Adverse outcomes were in keeping with previous reports, with no cases of occlusive retinal vasculitis.

conclusionsWe found that faricimab inactivated a significant proportion of CNV lesions that had been active using 1st generation VEGF inhibitors, with a significant extension of the treatment interval. A small reduction in VA occurred in switchers and eyes not switched through the same period.

Indexed as

Drug SubstitutionRegistriesWet Macular DegenerationAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, BispecificBevacizumabFemaleFluorescein AngiographyFollow-Up StudiesHumansIntravitreal InjectionsMaleRanibizumabReceptors, Vascular Endothelial Growth FactorafliberceptAngiogenesis InhibitorsAntibodies, BispecificBevacizumabfaricimabRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AVEGFA protein, humanAMDFaricimabmaculaneovascularswitching

Identifiers

PMID40716957
PMCPMC12747468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.